论文部分内容阅读
目的:对低分子肝素钙治疗肺心病并呼吸衰竭临床治疗效果进行分析。方法:随机选取2013年8月至2014年12月之间于我院进行疾病治疗的肺心病合并呼吸衰竭患者160例,随机分为两组。对照组肺心病并呼吸衰竭患者采取常规治疗,而试验组于常规治疗基础上采用低分子肝素钙治疗。观察比较两组患者的临床疗效。结果:对照组肺心病合并呼吸衰竭患者治疗总有效率67.50%低于试验组的总有效例率90.00%,即试验组患者的临床疗效更为显著,P<0.05。结论:临床治疗肺心病合并呼吸衰竭疾病时,于常规治疗的基础上采用低分子肝素钙药物治疗可以有效的改善患者的临床治疗效果,疗效显著。
Objective: To analyze the clinical effect of low molecular weight heparin in treating pulmonary heart disease and respiratory failure. Methods: A total of 160 patients with pulmonary heart disease complicated with respiratory failure who were treated in our hospital from August 2013 to December 2014 were randomly selected and divided into two groups at random. Control group of patients with pulmonary heart disease and respiratory failure to take conventional treatment, while the experimental group on the basis of conventional treatment with low molecular weight heparin treatment. Observed and compared the clinical efficacy of two groups of patients. Results: The total effective rate of the control group was 67.50% lower than that of the experimental group (90.00%), that is, the clinical efficacy of the test group was more significant (P <0.05). Conclusion: When treating pulmonary heart disease complicated with respiratory failure, low molecular weight heparin calcium therapy can effectively improve the therapeutic effect of patients on the basis of routine treatment, and the curative effect is remarkable.